Table 2 Publications reporting on the treatment of AOSD with IL-1 inhibitors
Study | Design | Patients | IL-1 treatment |
|---|---|---|---|
Fitzgerald et al. [57] | Case series | 4 patients with refractory AOSD | Anakinra |
Kalliolias et al. [58] | Case series | 4 patients with refractory AOSD | Anakinra |
Kötter et al. [59] | Case series | 4 patients with refractory AOSD | Anakinra |
Lequerre et al. [60] | Multicenter, retrospective observational study | 35 patients (20 SJIA, 15 AOSD) | Anakinra |
Franchini et al. [8] | Retrospective chart review | 49 patients with AOSD; 6 treated with biologics | Anakinra (n = 5) |
Henderson et al. (abstract) [61] | Prospective, open-label, dose escalation study | 5 patients with AOSD | Rilonacept |
Naumann et al. [62] | Case series | 8 patients with refractory AOSD (3 with systemic disease, 5 with articular disease) | Anakinra |
Laskari et al. [63] | Case series | 25 patients with refractory AOSD | Anakinra |
Riera et al. [64] | Retrospective review | 41 patients; 7 treated with biologics | Anakinra (n = 5) |
Nordstrom et al. [18] | Open, multicenter RCT | 22 patients with AOSD | Anakinra (n = 12) or DMARD (n = 10) |
Quartuccio et al. [65] | Retrospective, observational study | 36 patients with AOSD | Anakinra (n = 10) |
Giampietro et al. [66] | Retrospective, observational study | 28 patients with AOSD | Anakinra |
Iliou et al. [67] | Retrospective observational study | 44 patients with AOSD; 10 treated with anakinra | Anakinra |
Gerfaud-Valentin et al. [68] | Retrospective observational study | 57 patients with AOSD; 6 treated with anakinra | Anakinra |
Hong et al. [69] | Meta-analysis | 8 studies, 134 patients with AOSD | Anakinra |
Maria et al. [6] | Case series | 8 patients with refractory AOSD treated with biologics; 4 treated with IL-1 inhibitors | Anakinra, canakinumab |
Cavalli et al. [70] | Retrospective observational study | 20 patients with AOSD; 16 treated with anakinra, as first biologic option; eventually all patients received anakinra | Anakinra |
Ortiz-Sanjuán et al. [71] | Multicenter, open-label, retrospective study | 41 patients with AOSD refractory to standard immunosuppressive therapy and to other biologics | Anakinra |
Palmou et al. (abstract) [72] | Multicenter, open-label study | 75 patients with AOSD refractory to standard immunosuppressive therapy and to other biologics | Tocilizumab (n = 34) or anakinra (n = 41) |
Rossi-Semerano et al. [73] | Retrospective, observational study | 189 patients (35 AOSD, 27 SJIA) | Anakinra, canakinumab |
Lenert and Yao [35] | Case series | 7 patients with AOSD and MAS | Anakinra (n = 5) |
Sfriso et al. [74] | Multicenter, retrospective observational study | 245 patients with AOSD | 58 patients (23.7%) treated with biologics; anakinra as the first-line biologic (n = 31) or as the second-line biologic (n = 4) |
Toz et al. (abstract) [75] | Retrospective analysis of database | 24 patients with refractory AOSD; 7 treated with anakinra | Anakinra |
Colafrancesco et al. [76] | Multicenter retrospective observational study | 140 patients with refractory AOSD; all treated with anakinra; 4 switched to canakinumab after anakinra failure | Anakinra, canakinumab |
Junge et al. [77] | Comprehensive literature review with data summaries | 45 articles, > 150 patients with AOSD | Anakinra, canakinumab, rilonacept |
Feist et al. [33] | Subgroup analysis of pooled data from 4 SJIA studies | 29 older adolescents/younger adults with SJIA, considered representative of patients with AOSD | Canakinumab |
Neel et al. [78] | Multicenter retrospective observational study and systematic literature review | 20 patients with AOSD admitted to ICU; 5 patients received anakinra | Anakinra |